Dutch Company Receives High Growth Award 2012

Informations

• Publié par: polyganics
• Nombre de lectures: 10
• Langue: English

Extrait

Dutch Company Receives High Growth Award 2012

PR Newswire GRONINGEN, The Netherlands, November 30, 2012

GRONINGEN, The Netherlands,November 30, 2012/PRNewswire/ --

Polyganics, an independent biomedical company, has won the High Growth Award 2012. The High Growth Award is a prize for Dutch companies that combine growth, both in quality and quantity, with a clear vision of the future. Polyganics effectively proves that entrepreneurship and innovation continue to bear fruit, even in the current economic climate.

Groundbreaking contribution to health care

Polyganics has a leading patents portfolio in the field of biodegradable materials and related medical applications. The company was founded in 1999 as a spin-off of the University Medical Centre Groningen, The Netherlands. Close collaboration between Polyganics and the UMC Groningen has led to a groundbreaking contribution in the innovation of medical applications that are now used worldwide. Polyganics develops and makes products that are currently used worldwide by surgeons on millions of patients.

Continued investment

As an innovative, autonomous Dutch company, Polyganics invests continuously in the growth of knowledge, medical applications, production and the global use of bioresorbable (degradable) surgical solutions. These help surgeons to achieve optimal results for patients undergoing an ENT, neurological or intestinal operation. Polyganics develops these medical tools using two patented technology platforms of biodegradable synthetic polymers. The residual products are processed and excreted by the body. This makes the products very patient-friendly, safe and cost-effective, as no further surgery is required in order to remove implants. ® ® Well-known products are NASOPORE and NEUROLAC . Polyganics expects in 2013 to receive the results of an ® international study into the application of its new product C-SEAL , which was carried out among 600 patients with intestinal cancer.

Vision of growth

Polyganics grows by applying its own technology tow ards expanding its product range with innovations for the current market. This results in a shorter payback time for innovations and a stronger cash flow for the second growth phase. This parallel second line of approach ensures that the available technology and new developments are applied for adjoining surgical markets. Innovations are always aimed at providing a solution to current medical problems, preferably using patentable solutions, such as bowel leakage and surgical bleeding. Polyganics meets the needs of doctors and commercial partners all over the world.

http://www.polyganics.com/

For further information, contact Romke Ribbels, Marketing Manager, [phone]